111 results
Search Results
2. Survivorship – the situation room.
- Author
-
Dalton, Susanne Oksbjerg and Johansen, Christoffer
- Subjects
TUMOR treatment ,CANCER patient psychology ,SERIAL publications ,SURVIVAL rate ,DOCUMENTATION ,NEED (Psychology) ,CANCER patient medical care ,CANCER patient rehabilitation - Abstract
The article offers a perspective on survivorship situation in cancer patients. Emphasis is given on the need to address psychosocial problems such as depression and anxiety in cancer patients. Survivorship research papers are cited on topics including interventions addressing late effects such as neuropathy or bone density, role of patient-reported outcomes in cancer management and follow-up care, and effect of breast cancer treatment on sexuality.
- Published
- 2023
- Full Text
- View/download PDF
3. Comparison between Swedish EORTC QLQ-C30 general population norm data published in 2000 and 2019.
- Author
-
Johansson, Hemming, Lagergren, Pernilla, Nolte, Sandra, and Brandberg, Yvonne
- Subjects
TUMOR treatment ,CANCER patient psychology ,REFERENCE values ,CONFIDENCE intervals ,FUNCTIONAL status ,HEALTH status indicators ,COGNITION ,PHYSICAL activity ,QUALITY of life ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,RESEARCH funding ,EMOTIONS - Abstract
Normative health-related quality of life (HRQoL) data from the general population are regularly used to facilitate the interpretation of HRQoL as reported by cancer patients participating in cancer clinical trials, especially when conducting long-term follow-up studies after treatment. The aim of the present study is to compare two Swedish normative data sets, published in 2000 and 2019 respectively, and explore whether HRQoL as reported by the Swedish general population has changed over time. 'Sample 2000' was comprised of normative data from the Swedish general population who responded to the EORTC QLQ-C30 in a Swedish mail survey in 1999 (n = 3069). 'Sample 2019' consisted of data from the Swedish general population collected as part of a European norm data study using online panels, published in 2019 (n = 1027). Data were analyzed stratified by sex and age (40–49; 50–59; 60–69; 70–79 years). For most of the subscales and single items, no age group differences between the two samples were found, with the exception of the oldest age group (70–79 years), where Sample 2019 generally showed better HRQoL as compared to Sample 2000. Lower (worse) levels of Global quality of life and higher (worse) levels of Dyspnoea were found in Sample 2019 for most age groups. There were no differences found between the samples for most EORTC QLQ-C30 subscales and single items, with the exception of the oldest age group of both sexes in Sample 2019 who reported better HRQoL on many variables. When deciding which normative dataset to use, the mode of data collection and age group have to be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Structural brain alterations following adult non-CNS cancers: a systematic review of the neuroimaging literature.
- Author
-
Amidi, Ali and Wu, Lisa M.
- Subjects
TUMOR treatment ,BRAIN ,COGNITION disorders ,MEDLINE ,NEURORADIOLOGY ,ONLINE information services ,SYSTEMATIC reviews ,TREATMENT effectiveness ,ADULTS - Abstract
Background: Cancer and cancer treatments may impact the brain through several pathways leading to cognitive impairment. Neuroimaging evidence has begun to elucidate the neurobiological underpinnings of cancer-related cognitive impairment. The aim of this paper was to systematically review available literature on structural brain alterations following adult non-central nervous system (CNS) cancers and associated treatments. Methods: This review followed PRISMA guidelines and was registered in PROSPERO (ID#107387). Comprehensive searches were conducted in June 2018 using PubMed and Web of Science. Inclusion criteria were English peer-reviewed journal articles of formal, controlled studies that examined structural neuroimaging outcomes in adult non-CNS cancer patients and survivors. Selected articles were assessed for quality and risk of bias using the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Results: Thirty-six publications of prospective and cross-sectional studies met inclusion criteria and were included. Structural brain alterations following cancer and its treatment were reported in a majority of the publications as evidenced by reduced global and local gray matter volumes, impaired white matter microstructural integrity, and brain network alterations. Structural alterations were most often evident when cancer-treated groups were compared with healthy controls, and more subtle when compared with cancer controls. Regarding the existence of pretreatment impairments, the evidence was equivocal. There was significant between-study heterogeneity in imaging analytical approaches and use of statistical adjustments. Over half reported associations with cognitive outcomes, though regions and associated cognitive domains were heterogeneous. Conclusions: Structural brain alterations following cancer and cancer treatments were reported in a majority of the reviewed studies. However, the extent of observed alterations depended on the choice of comparison groups. Methodological issues exist that will need to be addressed systematically to ensure the validity of findings. Large-scale prospective studies with extended assessment points are warranted to replicate and build upon initial findings. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases.
- Author
-
Gehl, Julie, Sersa, Gregor, Matthiessen, Louise Wichman, Muir, Tobian, Soden, Declan, Occhini, Antonio, Quaglino, Pietro, Curatolo, Pietro, Campana, Luca G., Kunte, Christian, Clover, A. James P., Bertino, Giulia, Farricha, Victor, Odili, Joy, Dahlstrom, Karin, Benazzo, Marco, and Mir, Lluis M.
- Subjects
CANCER treatment ,METASTASIS ,ANTINEOPLASTIC agents ,CANCER chemotherapy ,CELL membranes ,DECISION making ,ELECTROTHERAPEUTICS ,SKIN tumors ,OPERATIVE surgery ,TREATMENT effectiveness ,TUMOR treatment - Abstract
Electrochemotherapy is now in routine clinical use to treat cutaneous metastases of any histology, and is listed in national and international guidelines for cutaneous metastases and primary skin cancer. Electrochemotherapy is used by dermatologists, surgeons, and oncologists, and for different degrees and manifestations of metastases to skin and primary skin tumours not amenable to surgery. This treatment utilises electric pulses to permeabilize cell membranes in tumours, thus allowing a dramatic increase of the cytotoxicity of anti-cancer agents. Response rates, often after only one treatment, are very high across all tumour types. The most frequent indications are cutaneous metastases from malignant melanoma and breast cancer. In 2006, standard operating procedures (SOPs) were written for this novel technology, greatly facilitating introduction and dissemination of the therapy. Since then considerable experience has been obtained treating a wider range of tumour histologies and increasing size of tumours which was not originally thought possible. A pan-European expert panel drawn from a range of disciplines from dermatology, general surgery, head and neck surgery, plastic surgery, and oncology met to form a consensus opinion to update the SOPs based on the experience obtained. This paper contains these updated recommendations for indications for electrochemotherapy, pretreatment information and evaluation, treatment choices, as well as follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Magnetic resonance-only simulation and dose calculation in external beam radiation therapy: a feasibility study for pelvic cancers.
- Author
-
Deppe, Martin H., Kemppainen, Reko, Suilamo, Sami, Keyriläinen, Jani, Lindholm, Paula, and Tuokkola, Terhi
- Subjects
RECTUM tumors ,PROSTATE tumors treatment ,PELVIC tumors ,COMPUTED tomography ,CONFIDENCE intervals ,FEMALE reproductive organ tumors ,MAGNETIC resonance imaging ,PHARMACEUTICAL arithmetic ,RADIATION ,PILOT projects ,PATIENT selection ,DATA analysis software ,DESCRIPTIVE statistics ,MANN Whitney U Test ,TUMOR treatment - Abstract
Background:The clinical feasibility of using pseudo-computed tomography (pCT) images derived from magnetic resonance (MR) images for external bean radiation therapy (EBRT) planning for prostate cancer patients has been well demonstrated. This paper investigates the feasibility of applying an MR-derived, pCT planning approach to additional types of cancer in the pelvis. Material and methods:Fifteen patients (five prostate cancer patients, five rectal cancer patients, and five gynecological cancer patients) receiving EBRT at Turku University Hospital (Turku, Finland) were included in the study. Images from an MRCAT (Magnetic Resonance for Calculating ATtenuation, Philips, Vantaa, Finland) pCT method were generated as a part of a clinical MR-simulation procedure. Dose calculation accuracy was assessed by comparing the pCT-based calculation with a CT-based calculation. In addition, the degree of geometric accuracy was studied. Results:The median relative difference of PTV mean dose between CT and pCT images was within 0.8% for all tumor types. When assessing the tumor site-specific accuracy, the median [range] relative dose differences to the PTV mean were 0.7 [−0.11;1.05]% for the prostate cases, 0.3 [−0.25;0.57]% for the rectal cases, and 0.09 [−0.69;0.25]% for the gynecological cancer cases. System-induced geometric distortion was measured to be less than 1 mm for all PTV volumes and the effect on the PTV median dose was less than 0.1%. Conclusions:According to the comparison, using pCT for clinical EBRT planning and dose calculation in the three investigated types of pelvic cancers is feasible. Further studies are required to demonstrate the applicability to a larger cohort of patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
7. Childhood cancer survivor cohorts in Europe.
- Author
-
Winther, Jeanette F., Kenborg, Line, Byrne, Julianne, Hjorth, Lars, Kaatsch, Peter, Kremer, Leontien C. M., Kuehni, Claudia E., Auquier, Pascal, Michel, Gérard, de Vathaire, Florent, Haupt, Riccardo, Skinner, Roderick, Madanat-Harjuoja, Laura M., Tryggvadottir, Laufey, Wesenberg, Finn, Reulen, Raoul C., Grabow, Desiree, Ronckers, Cecile M., van Dulmen-den Broeder, Eline, and van den Heuvel-Eibrink, Marry M.
- Subjects
CANCER chemotherapy ,CANCER patients ,MEDICAL screening ,QUALITY of life ,RADIOTHERAPY ,DISEASE complications ,TUMORS in children ,TUMOR treatment - Abstract
With the advent of multimodality therapy, the overall five-year survival rate from childhood cancer has improved considerably now exceeding 80% in developed European countries. This growing cohort of survivors, with many years of life ahead of them, has raised the necessity for knowledge concerning the risks of adverse long-term sequelae of the life-saving treatments in order to provide optimal screening and care and to identify and provide adequate interventions. Childhood cancer survivor cohorts in Europe. Considerable advantages exist to study late effects in individuals treated for childhood cancer in a European context, including the complementary advantages of large population-based cancer registries and the unrivalled opportunities to study lifetime risks, together with rich and detailed hospital-based cohorts which fill many of the gaps left by the large-scale population-based studies, such as sparse treatment information. Several large national cohorts have been established within Europe to study late effects in individuals treated for childhood cancer including the Nordic Adult Life after Childhood Cancer in Scandinavia study (ALiCCS), the British Childhood Cancer Survivor Study (BCCSS), the Dutch Childhood Oncology Group (DCOG) LATER study, and the Swiss Childhood Cancer Survivor Study (SCCSS). Furthermore, there are other large cohorts, which may eventually become national in scope including the French Childhood Cancer Survivor Study (FCCSS), the French Childhood Cancer Survivor Study for Leukaemia (LEA), and the Italian Study on off-therapy Childhood Cancer Survivors (OTR). In recent years significant steps have been taken to extend these national studies into a larger pan-European context through the establishment of two large consortia - PanCareSurFup and PanCareLIFE. The purpose of this paper is to present an overview of the current large, national and pan-European studies of late effects after childhood cancer. This overview will highlight the strong cooperation across Europe, in particular the EU-funded collaborative research projects PanCareSurFup and PanCareLIFE. Overall goal. The overall goal of these large cohort studies is to provide every European childhood cancer survivor with better care and better long-term health so that they reach their full potential, and to the degree possible, enjoy the same quality of life and opportunities as their peers. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. The effect of a smoking cessation program for patients in cancer treatment: a quasi-experimental intervention study.
- Author
-
Kvaavik, Elisabeth, Weemes Grøtting, Maja, Halkjelsvik, Torleif, van Helvoirt, Rene, Kirkhorn, Ingeborg Hjertvik, Bjaanes, Maria Moksnes, Tøndel, Hanne, Sværen, Julia Thue, Gripsgård, Helga, Byrkje, Kristin, and Helleve, Arnfinn
- Subjects
TUMOR treatment ,EVALUATION of human services programs ,SMOKING cessation ,CONFIDENCE intervals ,HUMAN research subjects ,CLINICAL trials ,MOTIVATIONAL interviewing ,RESEARCH methodology ,SELF-evaluation ,AGE distribution ,CANCER patients ,PRE-tests & post-tests ,SEX distribution ,DESCRIPTIVE statistics ,RESEARCH funding ,CONTROL groups ,SMOKING ,LABOR market ,SMOKING cessation products ,EDUCATIONAL attainment - Abstract
Compared to non-smokers, smokers have reduced effects of cancer treatment, and increased risk of treatment-related toxicity. Quitting smoking can improve treatment effects and reduce side effects. This study reports on the potential impact of a smoking cessation program on smoking cessation rates among patients in cancer treatment. Cancer patients 18 years and older who smoked, with survival prognosis ≥12 months, not suffering dementia or other mental illness, and who were referred to cancer treatment at six Norwegian hospitals were invited to participate. The study took place from 2017 to 2020 and used a pre-test-posttest non-equivalent control group design. The intervention group received structured smoking cessation guidance based on Motivational Interviewing combined with cost-free nicotine replacement products, while the control group received standard smoking cessation treatment. Self-reported smoking status were registered at baseline and at 6 months' follow up. 76% of patients smoked at baseline and 44% at follow-up in the intervention group, correspondingly 72% and 49% in the control group. In an analysis of differences in within-person change, the reduction in the intervention group was 13 percentage points larger (95% CI = (0.25, −0.005), p = 0.041). Adjusting for gender, age, education, labour market participation and partnership status did not attenuate the estimated effect (18 percentage point difference, 95% CI = (−0.346, −0.016), p = 0.032). Demographic factors and dropout rate differed somewhat between the groups with a higher dropout rate in the intervention group, 54% vs. 51%, respectively). Offering a structured smoking cessation program based on Motivational Interviewing and cost-free nicotine replacement products to cancer patients can increase cessation rates in comparison to standard smoking cessation care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Theoretical and practical outline of the Copenhagen PACT narrative-based exercise counselling manual to promote physical activity in post-therapy cancer survivors.
- Author
-
Midtgaard, Julie
- Subjects
TUMOR treatment ,CANCER patients ,CONCEPTUAL structures ,COUNSELING ,TUMORS ,SOCIAL support ,PHYSICAL activity ,DISEASE complications - Abstract
Background. Sedentary behaviour and reduced exercise capacity are potential persisting effects of anti-cancer therapy that may predispose to serious health conditions. It is well-established that physical exercise may prevent some of these problems. However, the extent to which cancer survivors are able to adopt long-term physical activity habits depends largely on their motivation. Aim. This theoretical paper aims to outline how researchers and practitioners can draw from Antonovsky's salutogenetic theory and White & Epston's Narrative Therapy to develop and implement intervention efforts centered on promotion of long-term physical activity behaviour, while at the same time increasing the individual cancer survivor's sense of meaning and personal health resources. Material and methods. The Copenhagen PACT (Physical Activity after Cancer Treatment) Study targeting adoption and maintenance of regular physical activity in post-therapy cancer survivors is briefly presented including a brief review of the theoretical rationale behind the psychological component of the intervention, i.e. a narrative-based exercise counselling programme. Subsequently, particular attention is given to the core principles, different components and structure of the counselling manual including sample questions and examples of written documents that have emanated from the individual counselling sessions. Discussion. The discussion includes consideration of some methodological challenges that arise when attempting to evaluate narrative-based interventions in the context of physical activity promotion in cancer rehabilitation and survivorship care. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review.
- Author
-
Yi Bin Pan, Maeda, Yasuko, Wilson, Ana, Glynne-Jones, Rob, and Vaizey, Carolynne J.
- Subjects
DIARRHEA ,GASTROINTESTINAL diseases ,ULCERS ,FECAL incontinence -- Risk factors ,ANAL tumors ,LONGITUDINAL method ,DOSE-response relationship (Radiation) ,QUALITY of life ,SYSTEMATIC reviews ,DISEASE incidence ,SEVERITY of illness index ,CHEMORADIOTHERAPY ,TUMOR treatment ,DISEASE risk factors - Abstract
Introduction: There is a paucity of data on incidence and mechanisms of long-term gastrointestinal consequences after chemoradiotherapy for anal cancer. Most of the adverse effects reported were based on traditional external beam radiotherapy whilst only short-term follow-ups have been available for intensity-modulated radiotherapy, and there is lack of knowledge about consequences of doseescalation radiotherapy. Method: A systematic literature review. Results: Two thousand nine hundred and eighty-five titles (excluding duplicates) were identified through the search; 130 articles were included in this review. The overall incidence of late gastrointestinal toxicity was reported to be 7-64.5%, with Grade 3 and above (classified as severe) up to 33.3%. The most commonly reported late toxicities were fecal incontinence (up to 44%), diarrhea (up to 26.7%), and ulceration (up to 22.6%). Diarrhea, fecal incontinence and buttock pain were associated with lower scores in radiotherapy specific quality of life scales (QLQ-CR29, QLQ-C30, and QLQ-CR38) compared to healthy controls. Intensity-modulated radiation therapy appears to reduce late toxicity. Conclusion: Late gastrointestinal toxicities are common with severe toxicity seen in one-third of the patients. These symptoms significantly impact on patients' quality of life. Prospective studies with control groups are needed to elucidate long-term toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Pitfalls in Estimating the Influence of Overall Treatment Time on Local Tumor Control.
- Author
-
Tucker, Susan L.
- Subjects
TUMOR treatment ,IRRADIATION - Abstract
Variations in the overall treatment time of human tumors occur for a number of reasons: differences in standard treatment schedules among centers, occurrence of public holidays during treatment, machine maintenance or breakdown, and decisions made by physicians to change treatment for individual patients based on patient or tumor response. It is now widely accepted that tumor proliferation can occur during treatment, and many efforts have been made to quantify the effects of varying the treatment time. Some of the many problems associated with obtaining quantitative estimates of the time factor are discussed. The aim of this paper is to illustrate that estimates of the time factor for tumor repopulation should be regarded with skepticism and used with extreme caution. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
12. Prevalence and risk factors for sexual dysfunction in young women following a cancer diagnosis – a population-based study.
- Author
-
Wettergren, Lena, Eriksson, Lars E., Bergström, Charlotta, Hedman, Christel, Ahlgren, Johan, Smedby, Karin E., Hellman, Kristina, Henriksson, Roger, and Lampic, Claudia
- Subjects
TUMOR treatment ,DYSPAREUNIA ,FEMALE reproductive organ diseases ,SEXUAL dysfunction ,MASTURBATION ,CROSS-sectional method ,HUMAN sexuality ,SEXUAL intercourse ,RISK assessment ,CANCER patients ,COMPARATIVE studies ,DISEASE prevalence ,DESCRIPTIVE statistics ,QUESTIONNAIRES ,TUMORS ,LOGISTIC regression analysis ,EMOTIONS ,HYPOACTIVE sexual desire disorder ,FEMALE reproductive organ tumors ,BREAST tumors ,PSYCHOLOGICAL distress ,BODY image ,DISEASE risk factors ,DISEASE complications ,ADULTS - Abstract
Self-reported sex problems among women diagnosed with reproductive and nonreproductive cancers before the age of 40 are not fully understood. This study aimed to determine sexual dysfunction in young women following a cancer diagnosis in relation to women of the general population. Furthermore, to identify factors associated with sexual dysfunction in women diagnosed with cancer. A population-based cross-sectional study with 694 young women was conducted 1.5 years after being diagnosed with cancer (response rate 72%). Potential participants were identified in national quality registries covering breast and gynecological cancer, lymphoma and brain tumors. The women with cancer were compared to a group of women drawn from the general population (N = 493). Sexual activity and function were assessed with the PROMIS® SexFS. Logistic regression was used to assess differences between women with cancer and the comparison group, and to identify factors associated with sexual dysfunction. The majority of the women with cancer (83%) as well as the women from the comparison group (87%) reported having had sex the last month (partner sex and/or masturbation). More than 60% of the women with cancer (all diagnoses) reported sexual dysfunction in at least one of the measured domains. The women with cancer reported statistically significantly more problems than women of the comparison group across domains such as decreased interest in having sex, and vaginal and vulvar discomfort. Women with gynecological or breast cancer and those receiving more intense treatment were at particular high risk of sexual dysfunction (≥2 domains). Concurrent emotional distress and body image disturbance were associated with more dysfunction. The results underscore the need to routinely assess sexual health in clinical care and follow-up. Based on the results, development of interventions to support women to cope with cancer-related sexual dysfunction is recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Twenty-five years with adjuvant chemotherapy for colon cancer - a continuous evolving concept.
- Author
-
Dahl, Olav and Pfeffer, Frank
- Subjects
COLON tumors ,COMBINED modality therapy ,SERIAL publications ,TUMOR classification ,TUMOR treatment - Abstract
The article offers information on the continuous research on chemotherapy for colon cancer. Topics discussed include use of intravenous 5-fluorouracil (5FU) chemotherapy in 1970s, combination of 5FU with the antihelmintic drug levamisol in 1989 and 1990 that improved disease-free survival (DFS) and cancer-specific survival (CSS), and current status of colon cancer patients with resected lymph node metastases that need to receive adjuvant chemotherapy.
- Published
- 2015
- Full Text
- View/download PDF
14. Is there a Nordic solution for the 'proton-problem'?
- Author
-
Bergfeldt, Kjell, Nystrom, Håkan, Witt Nystrom, Petra, and Høyer, Morten
- Subjects
TUMOR treatment ,CANCER patients ,CANCER treatment ,HEALTH facilities ,MEDICAL care costs ,RADIOTHERAPY ,SERIAL publications ,ADULT education workshops ,SPECIALTY hospitals ,PROTON therapy - Abstract
An introduction is presented in which the editor discusses several articles published within issue on topics including proton therapy indications and strategies for identification of patients for proton therapy, property of proton therapy, and patient's perspective in proton therapy.
- Published
- 2020
- Full Text
- View/download PDF
15. Decreasing access to cancer diagnosis and treatment during the COVID-19 pandemic in Poland.
- Author
-
Maluchnik, Michał, Podwójcic, Krzysztof, and Więckowska, Barbara
- Subjects
TUMOR diagnosis ,TUMOR treatment ,CANCER patients ,CANCER patient medical care ,CHEST tumors ,HEALTH services accessibility ,LABOR incentives ,INDUSTRIAL safety ,PAY for performance ,PATIENT safety ,REGRESSION analysis ,RESPIRATORY organ tumors ,SMART cards ,TUMORS ,GASTROINTESTINAL tumors ,GOVERNMENT aid ,MALE reproductive organ cancer ,DATA analysis software ,DESCRIPTIVE statistics ,COVID-19 pandemic - Abstract
In the article, the authors present their study on the effects of the COVID-19 pandemic in the access to cancer diagnosis and treatment to oncological patients in Poland. Also cited are the use of the DiLO card to facilitate diagnosis and treatment in the country and the National Health Fund as the responsible party in paying hospitals for procedures on oncological patients.
- Published
- 2021
- Full Text
- View/download PDF
16. Waiting times and treatment following cancer diagnosis: comparison between immigrants and the Norwegian host population.
- Author
-
Thøgersen, Håvard, Møller, Bjørn, Åsli, Linn Merete, Bhargava, Sameer, Kvåle, Rune, Fjellbirkeland, Lars, Robsahm, Trude Eid, Aaserud, Stein, Babigumira, Ronnie, and Larsen, Inger Kristin
- Subjects
BREAST tumor diagnosis ,BREAST tumor treatment ,TUMOR diagnosis ,TUMOR treatment ,TREATMENT of lung tumors ,PROSTATE tumors treatment ,COLON tumors ,CONFIDENCE intervals ,IMMIGRANTS ,LUNG tumors ,PROSTATE tumors ,RECTUM tumors ,TIME ,TUMORS ,LOGISTIC regression analysis ,PROPORTIONAL hazards models ,TREATMENT duration ,ODDS ratio - Abstract
Background: There are concerns about timely access to appropriate cancer treatment for the growing immigrant population in Norway. This study aims to compare waiting times between cancer diagnosis and start of cancer treatment, as well as treatment patterns between immigrants in Norway and the host population. Material and methods: We performed a nationwide, registry-based study with individual-level data, including 213,320 Norwegians and 8324 immigrants diagnosed with breast, colorectal, lung or prostate cancer in 1990–2014. Differences in time from diagnosis to treatment and in treatment patterns were described for the selected cancer sites. The Cox and logistic regressions were used to adjust for patient and tumour characteristics. Results: After adjustment for covariates, hazard ratios for time from diagnosis to treatment for non-Western immigrants compared to Norwegians were 0.88 (95% confidence interval (CI): 0.82–0.95) for breast cancer and 0.84 (95% CI: 0.75–0.95) for lung cancer, indicating longer waiting times. Treatment patterns in the four major cancer sites were similar among immigrants and the Norwegian host population, except for breast cancer, where women from East and South Asia received less breast-conserving surgery than the Norwegian host population (adjusted odds ratios 0.65 (95% CI: 0.46–0.93) for East Asians and 0.75 (95% CI: 0.50–1.13) for South Asians). Conclusions: The present study reports delayed treatment for lung and breast cancer among immigrants from non-Western countries in Norway. Systematic differences in cancer treatment were not detected. However, less breast-conserving surgery among breast cancer patients from Asia compared to Norwegians was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Smartphone apps to help children and adolescents with cancer and their families: a scoping review.
- Author
-
Mehdizadeh, Hamed, Asadi, Farkhondeh, Mehrvar, Azim, Nazemi, Eslam, and Emami, Hassan
- Subjects
DIAGNOSIS of tumors in children ,FAMILIES ,CANCER patient psychology ,COMMUNICATION ,CONCEPTUAL structures ,MEDICAL information storage & retrieval systems ,HEALTH policy ,MEDICINE information services ,MEDLINE ,ONLINE information services ,PATIENT education ,POLICY sciences ,TELEMEDICINE ,SYSTEMATIC reviews ,TUMORS in children ,SOCIAL support ,CAREGIVER attitudes ,SMARTPHONES ,MOBILE apps ,HEALTH information services ,FAMILY attitudes ,EDUCATION ,TUMOR treatment - Abstract
Introduction: Considering the importance of empowering patients and their families by providing appropriate information and education, it seems smartphone apps provide a good opportunity for this group. The purpose of this review was to identify studies which used smartphone apps to help children and adolescents with cancer and their families. Method: Arksey and O'Malley's framework was employed in this review. To examine the evidence on the design and use of smartphone apps for the target group, PubMed, Embase, Scopus and Web of Science databases were searched from 2007 to November 2018. Results: Twenty-four articles met the inclusion criteria, with 33% being conducted in the USA and 21% in Canada. Moreover, in 20 studies (83%), app was specifically designed for children and adolescents, with only three studies (13%) for parents and one study (4%) for both. The main modules of smartphone apps in these studies included symptom assessment (90%), provision of information and education (74%), communication with caregivers (57%), social support (30%) and calendar and reminder (21%). Conclusions: Due to the easy access to smartphones without a costly infrastructure compared to landline phones, the use of mobile health (m-Health) has become a suitable method of providing healthcare services, especially for cancer. Use of smartphone apps, increases patient and families' access to reliable and suitable education and information regarding the disease. Thus, healthcare policy-makers in developing or underdeveloped countries can exploit the health-related potentials of m-Health following the experience of developed countries. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Clinical evaluation and treatment of chronic bowel symptoms following cancer in the colon and pelvic organs.
- Author
-
Larsen, Helene Mathilde, Borre, Mette, Christensen, Peter, Mohr Drewes, Asbjørn, Laurberg, Søren, Krogh, Klaus, and Fassov, Janne
- Subjects
ANTIBIOTICS ,INTESTINAL disease diagnosis ,INTESTINAL disease treatment ,COLON tumors ,PELVIC tumors ,CHRONIC diseases ,DIET therapy ,INTESTINAL diseases ,LONGITUDINAL method ,HEALTH outcome assessment ,DESCRIPTIVE statistics ,SYMPTOMS ,TUMOR treatment - Abstract
Background: Chronic gastrointestinal symptoms are common among patients surviving surgery and/or radio-/chemotherapy for cancer in the pelvic organs. However, little is known about the pathophysiology behind symptoms or the effect of treatment. The aim of the present study was to present the results of clinical evaluation and treatment of patients with chronic bowel symptoms after treatment for cancer in the colon or pelvic organs. Material and methods: All patients referred to our department of gastroenterology between May 2016 and June 2018 with chronic bowel symptoms after treatment for cancer in the colon or pelvic organs were prospectively evaluated. Results: In total, 60 patients had been referred. The patients were treated for cancer in the right colon (n = 31), sigmoid colon (n = 1), rectum (n = 14), anal canal (n = 4), cervix uteri (n = 5), corpus uteri (n = 2), ovary (n = 2), and prostate (n = 1). The median time from cancer treatment to referral was 5.5 (range 1–36) years. Symptoms mainly included frequent bowel movements (65%), loose stools (87%), urgency for defecation (57%), and fecal incontinence (50%). A specific cause of bowel dysfunction was found in 48 (80%) of the patients and 21 (35%) had more than one cause of bowel symptoms. Bile acid malabsorption was present in 35 patients and small intestinal bacterial overgrowth was detected in 32. Treatment included bile acid sequestrants (n = 36), antibiotics (n = 33), loperamide (n = 21), and dietary intervention (n = 20). Major improvement in bowel symptoms was reported by 23 (38%) patients, while another 27 (45%) reported some improvement. Conclusion: Most patients with chronic bowel symptoms following cancer in the colon or pelvic organs will benefit from expert clinical evaluation and targeted treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. A longitudinal study of four unique trajectories of psychological distress in cancer survivors after completing potentially curative treatment.
- Author
-
Lotfi-Jam, Kerryann, Gough, Karla, Schofield, Penelope, Aranda, Sanchia, and Jefford, Michael
- Subjects
TUMOR treatment ,PSYCHOLOGICAL stress ,PSYCHOLOGICAL adaptation ,BREAST tumors ,CANCER patients ,COLON tumors ,LONGITUDINAL method ,PROSTATE tumors ,RECTUM tumors ,PSYCHOLOGICAL resilience ,TIME ,SOCIAL support ,HEMATOLOGIC malignancies ,BRIEF Symptom Inventory - Abstract
Background: Many survivors report short-term, transient psychological distress after cancer treatment. Some experience severe, worsening or persistent psychological morbidity which impairs functioning and warrants intervention. Using Bonanno's trajectories model, this study aimed to distinguish distress trajectories and to identify demographic, medical or psychosocial characteristics that differentiate those at risk of ongoing, clinically significant psychological distress. Methods: One-hundred and twenty-five cancer survivors of breast, prostate, colorectal or haematological cancers (response rate: 72%) completed measures of psychological distress (BSI-18), unmet needs (CASUN), social support (ESSI), coping styles (Mini-MAC), symptom prevalence (MSAS-SF) and benefit finding (PTGI) immediately after treatment and three and six months later. Distress and its predictors were investigated using linear mixed models. Groups based on Bonnano's trajectories were also compared on demographic, medical and psychosocial characteristics. Results: Changes in psychological distress over time were not statistically significant. Using BSI-18 clinical cut-off scores, most survivors (n = 65, 80%) were 'resilient', with stable, low distress levels. Almost one-tenth of survivors (n = 7, 9%) reported persistent, 'clinically significant' distress. Compared with the 'resilient' group, this 'chronic' group reported higher unmet needs, benefit finding, physical symptoms and poor coping styles, as well as lower social support immediately after treatment. They were also more likely to have a documented history of psychiatric illness. A 'recovered' group (n = 5, 6%) experienced high levels of distress that quickly returned to non-clinical levels and a delayed group (n = 4, 5%) reported initial low distress which worsened after treatment completion. Conclusions: Most survivors experience low distress (resilience) over time and may not require intense follow-up care. Screening for distress at the end of treatment may help to identify patients with more physical symptoms and unmet needs, less social support and higher use of maladaptive coping styles who are at risk of experiencing non-resilient trajectories of distress for further management of these symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. The use of PRO in adverse event identification during cancer therapy – choosing the right questions to ask.
- Author
-
Nissen, Aase, Bager, Louise, and Pappot, Helle
- Subjects
TUMOR treatment ,PROSTATE tumors treatment ,DOCUMENTATION ,EXPERIMENTAL design ,INTERVIEWING ,RESEARCH methodology ,METASTASIS ,PATIENT monitoring ,QUESTIONNAIRES ,RESEARCH methodology evaluation ,ADVERSE health care events - Abstract
Background: Adequate and timely monitoring of adverse events to cancer treatment is from our view dependent on a suitable Patient Reported Outcome (PRO) tool developed for the specific patient population based on cytostatic drugs included in the treatment. Therefore, a systematic method for construction of PRO questionnaires including selection of the appropriate questions is needed. Purpose: The purpose of the present study was to develop and test a method of item selection for a PRO questionnaire to monitor adverse events in oncologic routine treatment of metastatic prostate cancer patients. Patient and methods: Documentation on common symptomatic adverse events for the three drugs was collected from five different sources: 1) FDA product summary information; 2) EMA product summary information; 3) phase 3 Randomized Controlled Trials (RCT) leading to drug approval; 4) audit of the electronic patient files focusing on the oncologist's documentation of adverse events and 5) individual patient interview (n = 16) focusing on adverse events. The Patient Reported Outcome of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was used as PRO item library. Selected symptoms were transformed into corresponding PRO-CTCAE questions. The questionnaire was tested by patients in a pilot test (n = 12). Patients for interviews and pilot testing were included by purposive sampling. Results: A method for constructing a PRO questionnaire was developed, and a questionnaire of 25 PRO-CTCAE symptoms with 46 questions including an open write-in space for additional adverse events was constructed and tested. Conclusion: This study demonstrates a systematic method to select questions on adverse events for a PRO questionnaire in a specific cancer population receiving oncologic treatment. The present study reveals that audit of patient files and patient interviews in our setting only add little to the information on adverse events obtained from FDA, EMA and RCT. The obtained questionnaire was found useful and acceptable by patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Health-related quality of life in rectal cancer patients undergoing neoadjuvant chemoradiation with delayed surgery versus short-course radiotherapy with immediate surgery: a propensity score-matched cohort study.
- Author
-
Couwenberg, Alice M., Burbach, Johannes P. M., Intven, Martijn P. W., Consten, Esther C. J., Schiphorst, Anandi H. W., Smits, Anke B., Wijffels, Niels A. T., Heikens, Joost T., Koopman, Miriam, van Grevenstein, Wilhemina M. U., and Verkooijen, Helena M.
- Subjects
RECTUM tumors ,COMBINED modality therapy ,CONFIDENCE intervals ,DIGESTIVE organ surgery ,LONGITUDINAL method ,QUALITY of life ,QUESTIONNAIRES ,LOGISTIC regression analysis ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,ODDS ratio ,CHEMORADIOTHERAPY ,EVALUATION ,TUMOR treatment - Abstract
Background: Neoadjuvant chemoradiation with delayed surgery (CRT-DS) and short-course radiotherapy with immediate surgery (SCRT-IS) are two commonly used treatment strategies for rectal cancer. However, the optimal treatment strategy for patients with intermediate-risk rectal cancer remains a discussion. This study compares quality of life (QOL) between SCRT-IS and CRT-DS from diagnosis until 24 months after treatment. Methods: In a prospective colorectal cancer cohort, rectal cancer patients with clinical stage T2-3N0-2M0 undergoing SCRT-IS or CRT-DS between 2013 and 2017 were identified. QOL was assessed using EORTC-C30 and EORTC-CR29 questionnaires before the start of neoadjuvant treatment (baseline) and at 3, 6, 12, 18 and 24 months after. Patients were 1:1 matched using propensity sore matching. Between- and within-group differences in QOL domains were analyzed with linear mixed-effects models. Symptoms and sexual interest at 12 and 24 months were compared using logistic regression models. Results: 156 of 225 patients (69%) remained after matching. The CRT-DS group reported poorer emotional functioning at 3, 6, 12, 18 and 24 months (mean difference with SCRT-IS: −9.4, −12.1, −7.3, −8.0 and −7.9 respectively), and poorer global health, physical-, role-, social- and cognitive functioning at 6 months (mean difference with SCRT-IS: −9.1, −9.8, −14.0, −9.2 and −12.6, respectively). Besides emotional functioning, all QOL domains were comparable at 12, 18 and 24 months. Within-group changes showed a significant improvement of emotional functioning after baseline in the SCRT-IS group, whereas only a minor improvement was observed in the CRT-DS group. Symptoms and sexual interest in male patients at 12 and 24 months were comparable between the groups. Conclusions: In rectal cancer patients, CRT-DS may induce a stronger decline in short-term QOL than SCRT-IS. From 12 months onwards, QOL domains, symptoms and sexual interest in male patients were comparable between the groups. However, emotional functioning remained higher after SCRT-IS than after CRT-DS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Frailty status but not age predicts complications in elderly cancer patients: a follow-up study.
- Author
-
Ørum, Marianne, Gregersen, Merete, Jensen, Kenneth, Meldgaard, Peter, and Damsgaard, Else Marie S.
- Subjects
MENTAL depression risk factors ,HEAD tumors ,NECK tumors ,GASTROINTESTINAL tumors treatment ,TREATMENT of lung tumors ,MORTALITY risk factors ,RECTUM tumors ,COLON tumors ,THERAPEUTIC complications ,AGE distribution ,ELDER care ,GERIATRIC assessment ,CANCER patients ,COGNITION ,CONFIDENCE intervals ,FRAIL elderly ,HEALTH status indicators ,HOSPITAL wards ,HOSPITAL admission & discharge ,LONGITUDINAL method ,NUTRITIONAL assessment ,ONCOLOGY ,PALLIATIVE treatment ,PATIENTS ,COMORBIDITY ,ACTIVITIES of daily living ,TERMINATION of treatment ,MEDICAL records ,POLYPHARMACY ,ODDS ratio ,OLD age ,TUMOR treatment - Abstract
Objectives: The purposes were to investigate the health status of elderly cancer patients by comprehensive geriatric assessment (CGA) and to compare the complications with respect to baseline CGA and to evaluate the need for geriatric interventions in an elderly cancer patients' population. Material: Patients aged ≥70 years with lung cancer (LC), cancer of the head and neck (HNC), colorectal cancer (CRC), or upper gastro-intestinal cancer (UGIC) are referred to the Department of Oncology for cancer treatment. Methods: CGA was performed prior to cancer treatment and addressed the following domains: Activities of daily living (ADL), instrumental ADL (IADL), comorbidity, polypharmacy, nutrition, cognition, and depression. Complications, defined as dose reduction and discontinuation of treatment due to grade 3-4 toxicity, hospital admission, shift to palliative treatment, or death within 90 days, were identified from the medical files. Patients were classified as fit, vulnerable, or frail by CGA. Principal results: Patients (N=217) with a median age of 75 years (range: 70-93 yeas) were included: 13% were fit, 35% vulnerable, and 52% frail. CGA significantly predicted admittance to hospital in frail and vulnerable patients compared to fit patients: risk ratio (RR) 2.12 (95% CI: 1.01; 4.46). Vulnerable and frail patients had higher absolute risk of death within 90 days compared to fit patients: 7% and 23% versus 0%. HR for death within 90 days in frail patients as compared to vulnerable patients was 3.50 (95% CI: 1.34; 9.15). More frail patients (88%) needed geriatric interventions than the vulnerable (46%) and fit patients (32%). Major conclusion: Few elderly cancer patients seem to be fit. CGA predicts admittance to hospital in a population of elderly patients with mixed cancer diseases. Frail and vulnerable patients have higher risk of death within 90 days as compared to fit patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer.
- Author
-
Larue, Ruben T. H. M., Klaassen, Remy, Jochems, Arthur, Leijenaar, Ralph T. H., Hulshof, Maarten C. C. M., van Berge Henegouwen, Mark I., Schreurs, Wendy M. J., Sosef, Meindert N., van Elmpt, Wouter, vanLaarhoven, Hanneke W. M., and Lambin, Philippe
- Subjects
PACLITAXEL ,CARBOPLATIN ,COMPUTED tomography ,CONFIDENCE intervals ,RADIATION doses ,ESOPHAGEAL tumors ,SURVIVAL ,KAPLAN-Meier estimator ,CHEMORADIOTHERAPY ,PROGNOSIS ,TUMOR treatment ,THERAPEUTICS - Abstract
Background: Radiomic features retrieved from standard CT-images have shown prognostic power in several tumor sites. In this study, we investigated the prognostic value of pretreatment CT radiomic features to predict overall survival of esophageal cancer patients after chemoradiotherapy. Material and methods: Two datasets of independent centers were analyzed, consisting of esophageal cancer patients treated with concurrent chemotherapy (Carboplatin/Paclitaxel) and 41.4Gy radiotherapy, followed by surgery if feasible. In total, 1049 radiomic features were calculated from the primary tumor volume. Recursive feature elimination was performed to select the 40 most relevant predictors. Using these 40 features and six clinical variables as input, two random forest (RF) models predicting 3-year overall survival were developed. Results: In total 165 patients from center 1 and 74 patients from center 2 were used. The radiomicsbased RF model yielded an area under the curve (AUC) of 0.69 (95%CI 0.61-0.77), with the top-5 most important features for 3-year survival describing tumor heterogeneity after wavelet filtering. In the validation dataset, the RF model yielded an AUC of 0.61 (95%CI 0.47-0.75). Kaplan Meier plots were significantly different between risk groups in the training dataset (p=.027) and borderline significant in the validation dataset (p=.053). The clinical RF model yielded AUCs of 0.63 (95%CI 0.54-0.71) and 0.62 (95%CI 0.49-0.76) in the training and validation dataset, respectively. Risk groups did not reach a significant correlation with pathological response in the primary tumor. Conclusions: A RF model predicting 3-year overall survival based on pretreatment CT radiomic features was developed and validated in two independent datasets of esophageal cancer patients. The radiomics model had better prognostic power compared to the model using standard clinical variables. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Corrigendum.
- Subjects
CORONARY heart disease risk factors ,THYMUS tumors ,RADIOTHERAPY ,PROTON therapy ,TUMOR treatment - Abstract
A correction to the article related to the risk of cardiac events after adjuvant proton as compared to photon radiation therapy for patients with thymic malignancies is presented.
- Published
- 2018
- Full Text
- View/download PDF
25. Access to supportive care during and after cancer treatment and the impact of socioeconomic factors.
- Author
-
Sharp, Lena, Westman, Bodil, Olofsson, Anna, Leppänen, Arja, and Henriksson, Roger
- Subjects
TUMOR diagnosis ,TUMOR treatment ,HEAD tumors ,GASTROINTESTINAL tumors treatment ,NECK tumors ,GASTROINTESTINAL tumors ,HEMATOLOGIC malignancies ,MALE reproductive organs ,CANCER patient psychology ,FEMALE reproductive organ tumors ,COMBINED modality therapy ,REPORTING of diseases ,FOCUS groups ,HEALTH services accessibility ,MEDICAL referrals ,NURSING care plans ,HEALTH outcome assessment ,PALLIATIVE treatment ,PATIENT advocacy ,QUESTIONNAIRES ,LOGISTIC regression analysis ,SOCIOECONOMIC factors ,EDUCATIONAL attainment ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,DIAGNOSIS ,TUMORS ,THERAPEUTICS - Abstract
Background: Sweden's national cancer strategy points out several areas of cancer care that need improvements. Among them the need for supportive care resources to be accessible through the entire cancer trajectory and the reduction of socioeconomic inequalities. The aim of this study was to compare the patient-reported access to supportive care in the Stockholm-Gotland region between patients diagnosed in 2014 and 2016. The aim was also to describe how socioeconomic and other demographic factors impact access to supportive care. Material and methods: All patients with gynaecological, head and neck, haematological and upper gastrointestinal cancers diagnosed in the Stockholm-Gotland regions were identified through the Swedish Cancer Registries. Data were collected via a questionnaire on demographic, socioeconomic factors and patients' perception (n = 1872) of access to supportive care. Data were summarized using descriptive statistics and logistic regression was used for relevant variables. Results: Access to some supportive care resources, such as contact nurses (CNs) and individual written care plans (IWCPs) had significantly improved from 2014 to 2016. The proportion of patients that had received information about patient advocacy groups (PAGs) had also improved but remained on a relatively low level (29 and 35%, respectively). The proportion of patients being refereed to palliative care (PC) did not change between 2014 and 2016. In total, 10% of the patients reported to having received information on second medical opinion (SMO). Patients that had undergone multimodality cancer treatment were more likely to report access to supportive care, and those with lower education levels were more likely to have access to CNs and IWCPs. Conclusion: Access to some of the supportive care resources have shown improvements in the Stockholm-Gotland region but further efforts are required, especially regarding access to PC, information about PAGs and SMOs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
- Author
-
Zimmermann, Michel, Beer, Jürgen, Bodis, Stefan, von Moos, Roger, Vlachopoulou, Vasiliki, Zwahlen, Daniel R., and Oehler, Christoph
- Subjects
FLUOROURACIL ,CANCER treatment ,SQUAMOUS cell carcinoma ,ANAL tumors ,COMBINED modality therapy ,DIARRHEA ,GASTROINTESTINAL diseases ,LONGITUDINAL method ,MAGNETIC resonance imaging ,NEUTROPENIA ,RADIOTHERAPY ,SKIN inflammation ,SURVIVAL analysis (Biometry) ,POSITRON emission tomography ,TUMOR classification ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,TUMOR treatment - Abstract
Background:To evaluate local control (LC), survival and toxicity in anal cancer patients treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy at a single institution. Material and methods:From August 2010 to May 2015, 26 patients were treated at our institution with IMRT and concurrent 5-fluorouracil/mitomycin-C (5-FU/MMC) for localized squamous cell carcinoma of the anal canal (SCCAC). Radiotherapy (RT) with 50.4–60 Gy was delivered with a sequential boost in 31%, and a simultaneous-integrated boost (SIB-IMRT) in 69% of cases. Initial staging was based on PET-CT and MRI. Clinical measures of interest were the influence of PET-CT on staging and treatment planning, LC, disease free survival (DFS), overall survival (OS), colostomy free survival (CFS) and toxicities. Results:Median age was 61 years, 22 patients (85%) were female, and no patient was HIV-positive. The proportion of patients with stage I, II, IIIA and IIIB disease was 15%, 35%, 23% and 27%, respectively. PET-CT modified the extent of nodal disease in 9/23 cases (39%) and lead to major changes in treatment planning in 4/23 patients (17%). MRI was more accurate at identifying T4 disease. RT was delivered at full dose in 26 patients (100%) and chemotherapy in 22/26 patients (85%). Two patients (7.7%) required RT breaks. Median follow-up was 35 months [IQR: 19–52]. The 2-year LC, DFS, OS and CFS were 100%, 100%, 100% and 92%. Acute grade ≥3 dermatitis and diarrhea occurred in 73% and 8% of cases, respectively. Grade 3–4 neutropenia was seen in 10/23 patients (43%). Four patients (15%) developed chronic grade 2 GI toxicity. Conclusions:PET-CT provided additional information leading to major changes in treatment planning for 17% of patients. Considering our excellent outcomes, routine use of PET-CT as standard staging modality and IMRT planning procedure appears justified for patients with SCCAC. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
27. Sensitivity of post treatment positron emission tomography/computed tomography to detect inter-fractional range variations in scanned ion beam therapy.
- Author
-
Handrack, Josefine, Tessonnier, Thomas, Chen, Wenjing, Liebl, Jakob, Debus, Jürgen, Bauer, Julia, and Parodi, Katia
- Subjects
TUMOR treatment ,BIOLOGICAL models ,COMPUTED tomography ,MEDICAL errors ,RADIATION doses ,RADIATION measurements ,POSITRON emission tomography ,DESCRIPTIVE statistics ,PROTON therapy - Abstract
Background:Ion therapy, especially with modern scanning beam delivery, offers very sharp dose gradients for highly conformal cancer treatment. However, it is very sensitive to uncertainties of tissue stopping properties as well as to anatomical changes and setup errors, making range verification highly desirable. To this end, positron emission tomography (PET) can be used to measure decay products of β+-emitters created in interactions inside the patient. This work investigates the sensitivity of post treatment PET/CT (computed tomography) to detect inter-fractional range variations. Material and methods:Fourteen patients of different indication underwent PET/CT monitoring after selected treatment fractions with scanned proton or carbon ion beams. In addition to PET/CT measurements, PET and dose distributions were simulated on different co-registered CT data. Pairs of PET data were then analyzed in terms of longitudinal shifts along the beam path, as surrogate of inter-fractional range deviations. These findings were compared to changes of dose-volume-histogram indexes and corresponding dose as well as CT shifts to disentangle the origin of possible PET shifts. Results:Biological washout modeling (PET simulations) and low (<55 Bq/ml) activity concentrations (offline PET measurements, especially for12C ions) were the main limitations for clinical treatment verification. For two selected cases, the benefit of improved washout modeling based on organ segmentation could be demonstrated. Overall, inter-fractional range shifts up to ±3 mm could be deduced from both PET measurements and simulations, and found well correlated (typically within 1.8 mm) to anatomical changes derived from CT scans, in agreement with dose data. Conclusions:Despite known limitations of post treatment PET/CT imaging, this work indicates its potential for assessing inter-fractional changes and points to future developments for improved PET-based treatment verification. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Potential adverse effects to the retina of cancer therapy targeting pyruvate kinase M2.
- Author
-
Ng, Soo Khai, Wood, John P. M., Chidlow, Glyn, Peet, Daniel J., and Casson, Robert J.
- Subjects
TUMOR treatment ,DRUG side effects ,RETINA ,TRANSFERASES - Abstract
A letter to the editor in response to the article "On the origin of cancer cells" in a 1956 issue is presented.
- Published
- 2015
- Full Text
- View/download PDF
29. Improved treatment decisions in patients with esophageal cancer.
- Author
-
Amdal, Cecilie Delphin, Jacobsen, Anne-Birgitte, Falk, Ragnhild Sørum, Johnson, Egil, Os, Silje Skjelsvik, Warloe, Trond, and Bjordal, Kristin
- Subjects
AGE distribution ,ESOPHAGEAL tumors ,HEALTH care teams ,LONGITUDINAL method ,PALLIATIVE treatment ,QUALITY of life ,DECISION making in clinical medicine ,COMORBIDITY ,LOGISTIC regression analysis ,PROPORTIONAL hazards models ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,CANCER fatigue ,PROGNOSIS ,TUMOR treatment - Abstract
Background:Patients with esophageal cancer seldom achieve long-term survival. This prospective cohort study investigated the selection of patients likely to benefit from curative treatment and whether information on patients’ health-related quality of life (HRQL) would assist treatment decisions in the multidisciplinary team. Methods:Consecutive patients completed HRQL assessments and clinical data were collected before start of treatment. Logistic regression analyses identified clinical factors associated with treatment intent in patients with stage-III disease. Kaplan–Meier method was used for survival analyses and Cox proportional hazards models were used to assess the impact of clinical factors and HRQL on survival in patients planned for curative treatment. Results:Patients with curative treatment intent (n = 90) were younger, had better WHO performance status and less fatigue than patients with palliative treatment intent (n = 89). Median survival for the total cohort (n = 179) and patients with palliative or curative treatment intent was nine, five and 19 months, respectively. In multivariate Cox regression analyses, performance status (0–1 favorable) and comorbidity (ASA I favorable) were factors of importance for survival, whereas measures of HRQL were not. Conclusions:Patients performance status and comorbidity must be considered in addition to stage of disease to avoid extensive curative treatment in patients with short life expectancy. This study did not provide evidence to support that information on patients HRQL adds value to the multidisciplinary team’s treatment decision process. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
30. Admittance to specialized palliative care (SPC) of patients with an assessed need: a study from the Danish palliative care database (DPD).
- Author
-
Adsersen, Mathilde, Thygesen, Lau Caspar, Neergaard, Mette Asbjoern, Bonde Jensen, Anders, Sjøgren, Per, Damkier, Anette, and Groenvold, Mogens
- Subjects
TUMOR treatment ,CANCER patients ,DATABASES ,MEDICAL specialties & specialists ,PALLIATIVE treatment ,LOGISTIC regression analysis - Abstract
Background:Admittance to specialized palliative care (SPC) has been discussed in the literature, but previous studies examined exclusively those admitted, not those with an assessed need for SPC but not admitted. The aim was to investigate whether admittance to SPC for referred adult patients with cancer was related to sex, age, diagnosis, geographic region or referral unit. Material and methods:A register-based study with data from the Danish Palliative Care Database (DPD). From DPD we identified all adult patients with cancer, who died in 2010–2012 and who were referred to and assessed to have a need for SPC (N = 21,597).The associations were investigated using logistic regression models, which also evaluated whether time from referral to death influenced the associations. Results:In the adjusted analysis, we found that admittance was higher for younger patients [e.g., 50–59 versus 80 + years: odds ratio (OR) = 2.03; 1.78–2.33]. There was lower odds of admittance for patients with hematological malignancies and patients from two regions: Capital Region of Denmark and Region of Southern Denmark. Lower admittance among men and patients referred from hospital departments was explained by later referral. Conclusions:In this first nationwide study of admittance to SPC among patients with a SPC need, we found difference in admittance according to age, diagnosis and region. This indicates that prioritization of the limited resources means that certain subgroups with a documented need have reduced likelihood of admission to SPC. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
31. Bridging imaging and therapy: the role of medical physics in development of precision cancer care.
- Author
-
Malinen, Eirik, Waldeland, Einar, Hysing, Liv Bolstad, and Muren, Ludvig Paul
- Subjects
TUMOR treatment ,CANCER patient medical care ,COMPUTED tomography ,CONFERENCES & conventions ,DIAGNOSTIC imaging ,PHYSICS ,RADIOTHERAPY ,TUMOR classification - Abstract
The article reports on the usage of imaging techniques in the therapy administered to the cancer patients. Magnetic resonance imaging (MRI) and positron emission tomography (PET) could be used to assess disease extension and also to localize the most aggressive part of the disease in the patient. The issues raised at 4th symposium for the Nordic Association for Clinical Physics (NACP) are also discussed.
- Published
- 2017
- Full Text
- View/download PDF
32. Contouring and dose calculation in head and neck cancer radiotherapy after reduction of metal artifacts in CT images.
- Author
-
Christiansen, Rasmus Lübeck, Lorenzen, Ebbe Laugaard, Bertelsen, Anders Smedegaard, Hansen, Christian Rønn, Brink, Carsten, Eriksen, Jesper Grau, Asmussen, Jon Thor, Gyldenkerne, Niels, and Johansen, Jørgen
- Subjects
HEAD tumors ,NECK tumors ,PAROTID glands ,COMPUTED tomography ,DIAGNOSTIC imaging ,PHARMACEUTICAL arithmetic ,RADIOTHERAPY ,PLASTIC surgery ,MEDICAL artifacts ,ANATOMY ,DIAGNOSIS ,TUMOR treatment - Abstract
Background:Delineation accuracy of the gross tumor volume (GTV) in radiotherapy planning for head and neck (H&N) cancer is affected by computed tomography (CT) artifacts from metal implants which obscure identification of tumor as well as organs at risk (OAR). This study investigates the impact of metal artifact reduction (MAR) in H&N patients in terms of delineation consistency and dose calculation precision in radiation treatment planning. Material and methods:Tumor and OAR delineations were evaluated in planning CT scans of eleven oropharynx patients with streaking artifacts in the tumor region preceding curative radiotherapy (RT). The GTV-tumor (GTV-T), GTV-node and parotid glands were contoured by four independent observers on standard CT images and MAR images. Dose calculation was evaluated on thirty H&N patients with dental implants near the treated volume. For each patient, the dose derived from the clinical treatment plan using the standard image set was compared with the recalculated dose on the MAR image dataset. Results:Reduction of metal artifacts resulted in larger volumes of all delineated structures compared to standard reconstruction. The GTV-T and the parotids were on average 22% (p < 0.06) and 7% larger (p = 0.005), respectively, in the MAR image plan compared to the standard image plan. Dice index showed reduced inter-observer variations after reduction of metal artifacts for all structures. The average surface distance between contours of different observers improved using the MAR images for GTV and parotids (p = 0.04 andp = 0.01). The median volume receiving a dose difference larger than ±3% was 2.3 cm3(range 0–32 cm3). Conclusions:Delineation of structures in the head and neck were affected by metal artifacts and volumes were generally larger and more consistent after reduction of metal artifacts, however, only small changes were observed in the dose calculations. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
33. Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study.
- Author
-
Bergqvist, Jenny, Iderberg, Hanna, Mesterton, Johan, Bengtsson, Nils, Wettermark, Björn, and Henriksson, Roger
- Subjects
BRAIN tumor treatment ,GLIOMA treatment ,MENINGES ,AGE distribution ,BRAIN tumors ,EVALUATION of medical care ,MEDICAL care use ,MEDICAL protocols ,MENINGIOMA ,PRIMARY health care ,COMORBIDITY ,DESCRIPTIVE statistics ,TUMOR treatment ,PROGNOSIS ,TUMORS - Abstract
Background:Primary intracranial tumors are relatively uncommon and heterogeneous, which make them challenging to study. We coupled data from unique Swedish population-based registries in order to deeper analyze the most common intracranical tumor types. Patient characteristics (e.g. comorbidities), care process measures like adherence to national guidelines, healthcare resource use and clinical outcome was evaluated. Materials and methods:A register-based study including several population-based registries for all patients living in Stockholm-Gotland, diagnosed with primary intracranial tumor between 2001 and 2013 was performed. Patient characteristics were captured and investigated in relation to survival, healthcare resource use (inpatient-, outpatient- and primary care) and treatment process. Results:High-grade glioma and meningioma were the most common tumor types and most patients (76%) were above the age of 40 in the patient population (n = 3664). Older age, comorbidity (Elixhauser comorbidity index) and type of tumor (high-grade glioma) were associated with lower survival rate and increased use of healthcare resources, analyzed for patients living in Stockholm (n = 3031). The analyses of healthcare use and survival showed no differences between males and females, when stratifying by tumor types. Healthcare processes were not always consistent with existing national treatment recommendations for patients with high-grade gliomas (n = 474) with regard to specified lead times, analyzed in the Swedish Brain Tumor Registry, as also observed at the national level. Conclusions:Age, comorbidity and high-grade gliomas, but not sex, were associated with decreased survival and increased use of healthcare resources. Fewer patients than aimed for in national guidelines received care according to specified lead times. The analysis of comprehensive population-based register data can be used to improve future care processes and outcomes. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
34. Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up.
- Author
-
Jeppesen, Mette Moustgaard, Mogensen, Ole, Hansen, Dorte Gilså, Iachina, Maria, Korsholm, Malene, and Jensen, Pernille Tine
- Subjects
CANCER relapse ,ENDOMETRIAL tumors ,PATIENT aftercare ,LONGITUDINAL method ,STATISTICS ,SURVIVAL analysis (Biometry) ,UTERINE hemorrhage ,RETROSPECTIVE studies ,EARLY detection of cancer ,DIAGNOSIS ,TUMOR treatment - Abstract
Background:Considerable controversy remains as to the optimal organization of endometrial cancer follow-up. Aim:To evaluate the relationship between the way recurrence was detected and survival after treatment for endometrial cancer. Further, to identify characteristics associated with a pre-scheduled examination in women with symptomatic recurrence. Material and methods:All women with early stage endometrial cancer during 2005–2009 were included in a population-based historical cohort derived from the Danish Gynecological Cancer Database. Women diagnosed with recurrence within three years after primary surgery and the mode of recurrence detection were identified from hospital charts: asymptomatic recurrence detected at regular follow-up, symptomatic recurrence detected at regular follow-up or symptomatic recurrence detected in between follow-up. Survival of women with symptomatic and asymptomatic disease was compared. Furthermore, characteristics associated with self-referral as compared to presenting symptoms at regular follow-ups were identified using univariate analyses. Results:In total, 183 cases of recurrence (7%) were identified in the cohort of 2612 women. Of these, 65.5% were symptomatic with vaginal bleeding as the most prevalent symptom. Asymptomatic women had a significantly better three-year survival rate compared to symptomatic women (80.3% vs. 54.3%, p < 0.01). A total of 2.3% of the entire population had an asymptomatic recurrence. Women diagnosed at a pre-scheduled visit due to symptoms had a higher educational level (p = 0.03) and more often high-risk disease (p = 0.02) than symptomatic women diagnosed at regular follow-up. Conclusion:Early stage endometrial cancer carries a low risk of recurrence. Survival appears to be superior in asymptomatic patients, but length-time bias, i.e. the effect of aggressive tumor biology in symptomatic recurrences, may bias results in non-randomized controlled trials. Well educated patients with symptoms of recurrence more often sought medical attendance compared to less educated counterparts. This should be considered if patient-initiated follow-up is the standard care. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. Electrochemotherapy of mucosal head and neck tumors: a systematic review.
- Author
-
Plaschke, Christina Caroline, Gothelf, Anita, Gehl, Julie, and Wessel, Irene
- Subjects
HEAD tumors ,NECK tumors ,CANCER chemotherapy ,RESEARCH funding ,SYSTEMATIC reviews ,TREATMENT effectiveness ,ADVERSE health care events ,TUMOR treatment - Abstract
Background:Electrochemotherapy, the combination of electroporation and chemotherapy, is mainly used in the palliative setting for treatment of cutaneous and subcutaneous metastases; however, new applications are continuously being explored. Patients with head and neck cancer are primarily treated with surgery and/or radio-chemotherapy. In the setting of local recurrence with no further curative treatment options available, electrochemotherapy could be of value. We therefore performed a systematic search of the present literature. Materials and methods:Eligible studies presented data from patients with head and neck cancer treated across the mucosal surface with electrochemotherapy. The search resulted in 11 studies with a total of 72 patients. Results:Overall complete response was reported as good, especially in primary small tumors. Side effects were minor in primary tumors whereas large, recurrent tumors displayed more frequent side effects and some serious adverse events. Design and structure of the studies differed considerably, making general comparisons difficult. Conclusion:Few studies concerning electrochemotherapy on mucosal head and neck tumors are available and they are not easily comparable. Overall response to treatment is good; nonetheless, further systematic studies are warranted. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
36. Distinguishing recurrence and new primary tumor as well as the origin of neck metastases in head and neck cancer clinical trials by targeted DNA sequencing.
- Author
-
Lilja-Fischer, Jacob Kinggaard, Saksø, Mette, Stougaard, Magnus, Steiniche, Torben, and Overgaard, Jens
- Subjects
HEAD tumors ,NECK tumors ,CANCER relapse ,HUMAN dissection ,METASTASIS ,MOUTH tumors ,GENETIC mutation ,SQUAMOUS cell carcinoma ,TUMOR classification ,VETERINARY dissection ,TREATMENT effectiveness ,SEQUENCE analysis ,TUMOR treatment - Abstract
The article informs about the new primary tumor as well as the origin of neck metastases in head and neck cancer clinical trials. Topics discussed include neck squamous cell carcinoma have a high incidence of recurrences and new primary tumors; treatment decisions are mostly determined by feasibility of surgical resection or re-irradiation; and how to utilize the increasing availability of DNA sequencing to distinguish between local recurrence.
- Published
- 2019
- Full Text
- View/download PDF
37. Comments on 'High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis'.
- Author
-
Qu, Kunpeng, Gao, Peng, and Si, Ruohuang
- Subjects
THERAPEUTIC use of iodine isotopes ,RADIOISOTOPE therapy ,DRUG toxicity ,IODINE isotopes ,RADIOISOTOPES ,DATA analysis ,THYROID gland tumors ,RESEARCH bias ,ABLATION techniques ,TUMOR treatment - Abstract
A letter to the editor is presented in response to the article "High Versus Low Radioiodine Activity in Patients With Differentiated Thyroid Cancer: A Meta-Analysis" by A. Valachis et al.
- Published
- 2013
- Full Text
- View/download PDF
38. Extended survival after chemotherapy and conservative radiotherapy for HPV-16 positive stage IVB oropharyngeal carcinoma.
- Author
-
Ampil, Federico, Chaudhery, Shubnum, Devarakonda, Srinivas, and Mills, Glenn
- Subjects
SQUAMOUS cell carcinoma ,CANCER treatment ,PHARYNX tumors ,CANCER chemotherapy ,CHEST X rays ,COMBINED modality therapy ,PAPILLOMAVIRUSES ,RADIOTHERAPY ,SURVIVAL ,TUMOR classification ,DISEASE management ,TUMOR treatment - Abstract
A letter to the editor is presented which is concerned with the case of a 49 year old male patient with HPV-16 positive stage IVB oropharyngeal carcinoma who saw extended survival after chemotherapy and conservative radiotherapy.
- Published
- 2013
- Full Text
- View/download PDF
39. Outcomes of Bleomycin-based electrochemotherapy in patients with repeated loco-regional recurrences of vulvar cancer.
- Author
-
Pellegrino, Antonio, Damiani, Gianluca Raffaello, Mangioni, Costantino, Strippoli, Davide, Loverro, Giuseppe, Cappello, Antonio, Turoli Scd, Daniela, Corso, Silvia, Tartagni, Massimo, and Pezzotta, Maria Grazia
- Subjects
CANCER relapse ,VULVAR tumors ,BLEOMYCIN ,CANCER chemotherapy ,ELECTROTHERAPEUTICS ,INTRAVENOUS therapy ,QUALITY of life ,QUESTIONNAIRES ,TUMOR classification ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,TUMOR treatment ,CANCER treatment - Abstract
ObjectiveTo evaluate the safety, local tumor efficacy and relief of symptoms of electrochemotherapy (ECT) treatment in patients affected by recurrence of vulvar cancer (VC), unsuitable for standard treatments. MethodsTen patients were recruited with histological diagnosis of recurrence of VC. Intravenous bleomycin was injected, after an accurate mapping of all lesions and ECT was performed. Response to therapy was evaluated and quality of life (QoL) was evaluated via questionnaires. ResultsDiagnosis stage of primary tumors, according to the FIGO system, was: four patients respectively at stage IB (40%), and at stage II (40%), one patient at stage IIIA (10%), one patient with Paget cancer (10%). Mean age was 76 years (SD ± 7) at time of enrollment. Eight patients (80%) were previously submitted to surgery and/or radio-chemotherapy. Mean treatment time was 20 (range 10–20) min. After a median follow-up of 12 (3–22) months, six patients (60%) were alive. ConclusionsObjective responses (ORs) with local control of the tumor were obtained in 80%. After a mean follow-up of 12 (3–22) months six patients (60%) were alive. The favorable outcome of this study, indicates that ECT is a reliable treatment option that may improve their functioning, thus enhancing the care provided in the palliative setting. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
40. Failure pattern and salvage treatment after radical treatment of head and neck cancer.
- Author
-
Pagh, Anja, Grau, Cai, and Overgaard, Jens
- Subjects
CANCER treatment ,CANCER relapse ,HYPOPHARYNX ,ACADEMIC medical centers ,GLOTTIS ,PATIENT aftercare ,HEAD tumors ,TREATMENT effectiveness ,NECK tumors ,SALVAGE therapy ,EARLY diagnosis ,DESCRIPTIVE statistics ,TUMOR treatment ,DIAGNOSIS ,TUMORS ,PROGNOSIS - Abstract
PurposeThe aim of the study was to test the hypothesis that head and neck cancer (HNC) patients benefit from specialized follow-up (FU), as this strategy ensures timely detection of relapses for successful salvage treatment. This was done by evaluation of the pattern of failure, the temporal distribution of recurrences, and the outcome of salvage treatment in a contemporary cohort of HNC patients. MethodsThe study evaluated a cohort of 2062 consecutive patients treated with curative intent at Aarhus University Hospital from 1 January 2000 to 31 December 2013. The database of DAHANCA contained recordings of recurrent disease in 567 patients with primary tumors of the larynx, pharynx, oral cavity, nasal cavity, paranasal sinuses and salivary glands. A review of medical records was performed in order to update and supplement the database. ResultsFailures of the 567 patients were primarily in T-site (65%) followed by N-site (36%) and M-site (22%). The vast majority of the first recurrences occurred within the first years after primary treatment; 62%, 82%, and 91% within the first, second and third year, respectively. Totally, 51% were amenable for salvage treatment, and 44% benefited from salvage in terms of a complete response. Permanent tumor control was observed in 128 patients (23%) after one or two salvage attempts. The highest salvage rate was recorded in patients with primary glottic carcinoma (41%) and the lowest among hypopharyngeal cancers (2%). Asymptomatic recurrence was recorded in 12% of all recurrences and this was found to be a positive prognostic factor for disease-specific survival, as they had significantly better outcome after salvage. ConclusionOur data support the usefulness of specialized FU in terms of early detection of recurrent disease. In particular patients with silent recurrences benefited from early detection, as they had a significantly lower risk ratio of death from primary HNC. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
41. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.
- Author
-
Tabaksblat, Elizaveta Mitkina, Ladekarl, Morten, Langer, Seppo W., Knigge, Ulrich, Grønbæk, Henning, Mortensen, Jann, Petersen, René Horsleben, and Federspiel, Birgitte Hartnack
- Subjects
TREATMENT of lung tumors ,DIFFERENTIAL diagnosis ,BRONCHIAL tumors ,LUNG tumors ,NEUROENDOCRINE tumors ,ONCOLOGY ,TUMOR markers ,DISEASE management ,DIAGNOSIS ,TUMOR treatment - Abstract
Bronchopulmonary neuroendocrine tumours (BP-NET) are a heterogeneous population of neoplasms with different pathology, clinical behaviour and prognosis compared to the more common lung cancers. The management of BP-NET patients is largely based on studies with a low level of evidence and extrapolation of data obtained from more common types of neuroendocrine tumours. This review reflects our view of the current state of the art of diagnosis and treatment of patients with BP-NET. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
42. Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer.
- Author
-
Rao, Shyam D., Setton, Jeremy, Tam, Moses, McBride, Sean M., Riaz, Nadeem, Lee, Nancy Y., Saleh, Ziad H., and Deasy, Joseph O.
- Subjects
HEAD tumors ,NECK tumors ,MASTICATORY muscles ,MASSETER muscle ,COMPUTED tomography ,DRUG toxicity ,LARYNGEAL tumors ,DOSE-response relationship (Radiation) ,MEDICAL needs assessment ,NASOPHARYNX tumors ,PTERYGOID muscles ,SQUAMOUS cell carcinoma ,STATISTICS ,TEMPORALIS muscle ,TRISMUS ,TUMOR classification ,DATA analysis ,HYPOPHARYNX ,DATA analysis software ,OROPHARYNGEAL cancer ,CHEMORADIOTHERAPY ,DIAGNOSIS ,ANATOMY ,TUMORS ,TUMOR treatment - Abstract
Background.To investigate the dose-volume factors in mastication muscles that are implicated as possible causes of trismus in patients following treatment with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy for head and neck cancers. Material and methods.All evaluable patients treated at our institution between January 2004 and April 2009 with chemotherapy and IMRT for squamous cell cancers of the oropharynx, nasopharynx, hypopharynx or larynx were included in this analysis (N = 421). Trismus was assessed using CTCAE 4.0. Bi-lateral masseter, temporalis, lateral pterygoid and medial pterygoid muscles were delineated on axial computed tomography (CT) treatment planning images, and dose-volume parameters were extracted to investigate univariate and multimetric correlations. Results.Forty-six patients (10.9%) were observed to have chronic trismus of grade 1 or greater. From analysis of baseline patient characteristics, toxicity correlated with primary site and patient age. From dose-volume analysis, the steepest dose thresholds and highest correlations were seen for mean dose to ipsilateral masseter (Spearman's rank correlation coefficient Rs = 0.25) and medial pterygoid (Rs = 0.23) muscles. Lyman-Kutcher-Burman modeling showed highest correlations for the same muscles. The best correlation for multimetric logistic regression modeling was withV68Gyto the ipsilateral medial pterygoid (Rs = 0.29). Conclusion.Chemoradiation-induced trismus remains a problem particularly for patients with oropharyngeal carcinoma. Strong dose-volume correlations support the hypothesis that limiting dose to the ipsilateral masseter muscle and, in particular, the medial pterygoid muscle may reduce the likelihood of trismus. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
43. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010.
- Author
-
Guren, Marianne G., Kørner, Hartwig, Pfeffer, Frank, Myklebust, Tor Å., Eriksen, Morten T., Edna, Tom-Harald, Larsen, Stein G., Knudsen, Kristin O., Nesbakken, Arild, Wasmuth, Hans H., Vonen, Barthold, Hofsli, Eva, Færden, Arne E., Brændengen, Morten, Dahl, Olav, Steigen, Sonja E., Johansen, Magnar J., Lindsetmo, Rolv-Ole, Drolsum, Anders, and Tollåli, Geir
- Subjects
RECTUM tumors ,TREATMENT effectiveness ,REPORTING of diseases ,TIME ,TUMOR treatment - Abstract
Background.The Norwegian Rectal Cancer Project was initated in 1993 with the aims of improving surgery, decreasing local recurrence rates, improving survival, and establishing a national rectal cancer registry. Here we present results from the Norwegian Colorectal Cancer Registry (NCCR) from 1993 to 2010. Material and methods.A total of 15 193 patients were diagnosed with rectal cancer in Norway 1993–2010, and were registered with clinical data regarding diagnosis, treatment, locoregional recurrences and distant metastases. Of these, 10 796 with non-metastatic disease underwent tumour resection. The results were stratified into five time periods, and the treatment outcomes were compared. Recurrence rates are presented for the 9785 patients who underwent curative major resection (R0/R1). Results.Among all 15 193 patients, relative five-year survival increased from 54.1% in 1993–1997 to 63.4% in 2007–2010 (p < 0.001). Among the 10 796 patients with stage I–III disease who underwent tumour resection, from 1993–1997 to 2007–2010, relative five-year survival improved from 71.2% to 80.6% (p < 0.001). An increasing proportion of these patients underwent surgery at large-volume hospitals; and 30- and 100-day mortality rates, respectively, decreased from 3.0% to 1.4% (p < 0.001) and from 5.1% to 3.0% (p < 0.011). Use of preoperative chemoradiotherapy increased from 6.5% in 1993 to 39.0% in 2010 (p < 0.001). Estimated local recurrence rate after major resection (R0/R1) decreased from 14.5% in 1993–1997 to 5.0% in 2007–2009 (p < 0.001), and distant recurrence rate decreased from 26.0% to 20.2% (p < 0.001). Conclusion.Long-term outcomes from a national population-based rectal cancer registry are presented. Improvements in rectal cancer treatment have led to decreased recurrence rates of 5% and increased survival on a national level. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
44. Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer.
- Author
-
Intven, Martijn, Monninkhof, Evelyn M., Reerink, Onne, and Philippens, Marielle E.P.
- Subjects
RECTUM tumors ,COMBINED modality therapy ,MAGNETIC resonance imaging ,RESEARCH ,TUMOR classification ,CHEMORADIOTHERAPY ,CLASSIFICATION ,TUMOR treatment - Abstract
Background.To assess the value of combined T2-weighted magnetic resonance imaging (MRI) (T2w) volumetry, diffusion-weighted (DW)-MRI and dynamic contrast enhanced (DCE)-MRI for pathological response prediction after neo-adjuvant chemoradiation (CRT) in locally advanced rectal cancer (LARC). Material and methods.MRI with DW-MRI and DCE-MRI sequences was performed before start of CRT and before surgery. After surgery, the tumor regression grade (TRG) was obtained based on the score by Mandard et al. Pathological complete responders (pCR, TRG 1), and pathological good responders (GR, TRG 1 + 2) were compared to non-pCR and non-GR patients, respectively. Results.In total 55 patients were analyzed, six had a pCR (10.9%) and 10 a GR (18.2%). Favorable responders had a larger decrease in tumor volume and Ktrans and a larger increase in apparent diffusion coefficient (ADC) values compared to non-responders. ADC change showed the best diagnostic accuracy for pCR. For GR, the model including ADC change and volume change showed the best diagnostic performance. However, this performance was not statistically better compared to the model with ADC change alone. Inclusion of Ktrans change did not increase the diagnostic accuracy for pathological favorable response. Conclusions.This explorative study showed that ADC change is a promising diagnostic tool for pCR and GR. Volume decrease showed potential limited additional diagnostic value for GR while Ktrans change showed no additional diagnostic value for pCR and GR. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
45. The role of behavioural modification and exercise in the management of cancer-related fatigue to reduce its impact during and after cancer treatment.
- Author
-
Minton, Ollie, Jo, Foster, and Jane, Maher
- Subjects
CANCER complications ,TUMOR treatment ,FATIGUE (Physiology) ,BEHAVIOR modification ,CANCER patients ,EXERCISE therapy ,HEALTH promotion ,MEDICAL personnel ,PATIENT compliance ,TIME ,COMORBIDITY ,OCCUPATIONAL roles ,CANCER treatment ,THERAPEUTICS - Abstract
Background. Fatigue is a symptom that can occur during treatment as an acute side effect but can also result in persistent fatigue as a long-term side effect or late effect. Materials and methods. We undertook a narrative review of the current literature and discuss the current evidence of assessment of fatigue and we specifically focus on the role of promoting behavioural change and focused rehabilitation to minimise these long-term effects and update the literature relating to this area from 2012 to date. Results. We suggest there are behavioural change models that can be scaled up to enable patients to manage long-term fatigue using exercise. However, from this updated review there are limitations to the current infrastructure and evidence base that will impact on the ability to do this. Conclusion. We continually need to raise awareness amongst health professionals to continue to suggest modifications to impact on fatigue at all stages of cancer treatment and into survivorship and late effects. These can range from simple brief interventions suggested in the clinic to full scale rehabilitation programmes if the correct infrastructure is available. Whichever approach is adopted we suggest exercise will be the mainstay of the treatment of fatigue in this group. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Effects of rehabilitation among patients with advances cancer: a systematic review.
- Author
-
Salakari, Minna R. J., Surakka, Tiina, Nurminen, Raija, and Pylkkänen, Liisa
- Subjects
TUMOR treatment ,TUMORS & psychology ,PSYCHOLOGICAL adaptation ,CANCER patient rehabilitation ,EXERCISE ,FATIGUE (Physiology) ,INFORMATION storage & retrieval systems ,MEDICAL databases ,MEDLINE ,ONLINE information services ,PALLIATIVE treatment ,TUMORS ,TUMOR classification ,SYSTEMATIC reviews ,DISEASE complications - Abstract
Background. In parallel with the rising incidence of cancer and improved treatment, there is a continuous increase in the number of patients living with cancer as a chronic condition. Many cancer patients experience long-term disability and require continuous oncological treatment, care and support. The aim of this review is to evaluate the most recent data on the effects of rehabilitation among patients with advanced cancer. Material and methods. A systematic review was conducted according to Fink's model. Only randomized controlled trials (RCTs) published in 2009-2014 were included. Medline/PubMed and Cochrane databases were searched; five groups of keywords were used. The articles were evaluated for outcome and methodological quality. Results. Thirteen RCTs (1169 participants) were evaluated. Most studies were on the effects of physical exercise in patients with advanced cancer (N = 7). Physical exercise was associated with a significant improvement in general wellbeing and quality of life. Rehabilitation had positive effects on fatigue, general condition, mood, and coping with cancer. Conclusions. Rehabilitation is needed also among patients with advanced disease and in palliative care. Exercise improves physical performance and has positive effects on several other quality of life domains. More data and RCTs are needed, but current evidence gives an indication that rehabilitation is suitable and can be recommended for patients living with advanced cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
47. A longitudinal study of follow-up activities after curative treatment for head and neck cancer.
- Author
-
Pagh, Anja, Grau, Cai, and Overgaard, Jens
- Subjects
HEAD tumors ,NECK tumors ,CANCER relapse ,ACADEMIC medical centers ,CANCER patients ,CONFIDENCE intervals ,PATIENT aftercare ,LONGITUDINAL method ,RESEARCH funding ,DISEASE remission ,DATA analysis software ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,ODDS ratio ,DIAGNOSIS ,TUMOR treatment - Abstract
Purpose. To test the hypothesis that head and neck cancer (HNC) patients are in need of specialized follow-up (FU). This was done by an evaluation of the FU activities in a cohort of patients followed longitudinally for five years with focus on optimal duration and interval of post-therapeutic follow-up. Methods. The study evaluated a cohort consisting of 197 consecutive patients with HNC treated at Aarhus University Hospital from 1 January to 31 December 2009. The inclusion criteria was that patients should be deemed free of disease two months after completed primary curative intended treatment or after primary curative salvage. It left 141 patients available for analysis. Data were collected through a medical chart review and from the Danish Head and Neck Cancer Group (DAHANCA) database. Parameters recorded were: regular or extraordinary visit, alarm symptoms, late morbidity and the consequences of these. Results. The 141 patients underwent 1408 FU visits. Only 15 of the 141 patients had no tumor problems or morbidity issues raised at any FU visit. Suspicion of recurrent disease was observed at 207 of the 1408 FU visits, involving 97 patients and resulted in a total of 370 diagnostic procedures; 170 (82%) visits with suspicion of recurrence occurred within 3½ years after end of treatment. A recurrence was verified in 30 patients. Additionally four new primary head and neck cancer was diagnosed during follow-up. There were 1150 visits (82%) involving 135 patients in which late treatment-related morbidity was recorded. Actions taken related to morbidity happened in 71 patients, but no new problems appeared after three years. Conclusion. The study document the need of specialized FU, as 86% of all HNC survivors have tumor or severe morbidity issues during FU. The data suggest that 3½-year FU after ended therapy may be sufficient for the majority of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Integrated care pathways for cancer survivors - a role for patient-reported outcome measures and health informatics.
- Author
-
Warrington, Lorraine, Absolom, Kate, and Velikova, Galina
- Subjects
TUMOR treatment ,ALGORITHMS ,CANCER patients ,CONTINUING education ,COST effectiveness ,EVALUATION of medical care ,MEDICAL informatics ,MEDICAL protocols ,PATIENT compliance ,PATIENT education ,HEALTH self-care ,INTEGRATIVE medicine ,HUMAN services programs ,ELECTRONIC health records - Abstract
Modern cancer treatments have improved survival rates and changed the nature of cancer care. The acute and long-term physical and psychosocial comorbidities associated with treatment place increasing demands on healthcare services to provide suitable models of follow-up care for the survivor population. Aim. We discuss the value and challenges of incorporating patient-reported outcome measures (PROMs) and eHealth interventions into routine follow-up care. We draw on our 15 years' experience of developing electronic systems for capturing patient-reported data in oncology settings, with particular reference to eRAPID a new online symptom reporting system for cancer patients. The redesign of healthcare pathways. New stratified care pathways have been proposed for cancer survivors with an emphasis on supported self-management and shared care. The potential role of PROMs in survivorship care pathways. PROMs can be used to evaluate rehabilitation services, provide epidemiological 'Big Data' and screen patients for physical and psychological morbidities to determine the need for further support. In addition, electronic PROMs systems linked to electronic patient records (EPRs) have the capability to provide tailored self-management advice to individual patients. Integration of PROMs into clinical practice. The successful clinical utilisation of PROMs is dependent on a number of components including; choosing appropriate questionnaires, developing evidence-based scoring algorithms, the creation of robust electronic platforms for recording and transferring data into EPRs, and training staff and patients to engage effectively with PROMs. Discussion. There is increasingly positive evidence for using PROMs and eHealth approaches to support cancer patients' care during treatment. Much of what has been learnt can be applied to cancer survivorship. PROMs integrated into eHealth platforms and with EPR have the potential to play a valuable role in the development of appropriate and sustainable long-term follow-up models for cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
49. Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship.
- Author
-
Christensen, Jesper F., Bandak, Mikkel, Campbell, Anna, Jones, Lee W., and Højman, Pernille
- Subjects
CARDIOVASCULAR disease prevention ,GERMINOMA ,ANTIEMETICS ,CANCER chemotherapy ,CANCER patients ,CARDIOVASCULAR diseases ,CASTRATION ,COMBINED modality therapy ,EXERCISE therapy ,RADIOTHERAPY ,TESTIS tumors ,THERAPEUTICS ,TUMOR treatment - Abstract
Background. Treatment of testicular germ cell cancer constitutes a major success story in modern oncology. Today, the vast majority of patients are cured by a therapeutic strategy using one or more highly effective components including surgery (orchiectomy), radiotherapy and/or chemotherapy. However, the excellent cancer-specific survival comes at considerable costs, as individuals with a history of germ cell cancer experience serious long-term complications, including markedly increased risk of cardiovascular morbidities and premature cardiovascular death. The factors responsible, as well as their mode of action, are not fully understood and there is a lack of knowledge concerning optimal evidence-based long-term follow-up strategies. Results. Here, we present the growing body of evidence suggesting that germ cell cancer patients as a consequence of the different treatment components, are subjected to toxicities, which individually, and synergistically, can cause physiological impairments leading to sub-clinical or clinical cardiovascular disorders (i.e. the 'multiple-hit hypothesis'). Furthermore, we discuss the efficacy and utility of structured exercise training to ameliorate treatment-induced cardiovascular dysfunction to prevent premature onset of clinical cardiovascular disease in germ cell cancer survivors, with a view towards highlighting future directions of exercise-based survivorship research in the germ cell cancer setting. Conclusion. As exercise training may have the potential to ameliorate and/or reverse long-term cardiovascular disease sequelae in germ cell cancer survivors, a strong rationale exists for the promotion of exercise oncology research in this setting, in order to provide exercise recommendations for optimal germ cell cancer survivorship. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
50. Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?
- Author
-
Poulsen, Laurids Ø., Qvortrup, Camilla, Pfeiffer, Per, Yilmaz, Mette, Falkmer, Ursula, and Sorbye, Halfdan
- Subjects
RECTUM tumors ,COMBINED modality therapy ,DATA analysis software ,DESCRIPTIVE statistics ,PERIOPERATIVE care ,TUMOR treatment - Abstract
Background. The use of postoperative adjuvant chemotherapy is controversial for rectal adenocarcinoma. Both international and national guidelines display a great span varying from recommending no adjuvant chemotherapy at all, over single drug 5-fluororuacil (5-FU), to combinations of 5-FU/oxaliplatin. Methods. A review of the literature was made identifying 24 randomized controlled trials on adjuvant treatment of rectal cancer based on about 10 000 patients. The trials were subdivided into a number of clinically relevant subgroups. Results. As regards patients treated with preoperative (chemo) radiotherapy, four randomized studies were found where use of adjuvant chemotherapy showed no benefit in survival. Three trials were found in which a subset of patients received preoperative (chemo) radiotherapy. Two of these trials showed a statistically significant benefit of adjuvant chemotherapy. Twenty trials were identified in which the patients did not receive preoperative (chemo) radiotherapy, including five Asian studies in which a statistically significant benefit from adjuvant chemotherapy was reported. Conclusions. Most of the data found did not support the use of postoperative adjuvant chemotherapy for patients already treated with preoperative (chemo) radiotherapy. For patients not treated preoperatively, several studies support the use of single agent 5-FU chemotherapy. Treatment guidelines seem to differ according to if preoperative chemoradiation is considered of importance for use of adjuvant chemotherapy and if adjuvant colon cancer studies are considered transferrable to rectal cancer patients regardless of the molecular differences. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.